BioCardia Inc is a clinical-stage company developing cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases with unmet medical needs. Its two cell therapy platforms derived from the bone marrow. CardiAMP autologous mononuclear cell therapy platform is being for two clinical indications: ischemic heart failure with reduced ejection fraction (HFrEF) and refractory angina resulting from chronic myocardial ischemia (CMI). Its immunomodulatory allogeneic mesenchymal stem cell (MSC) therapy platform is being an off the shelf cell therapy for two clinical indications: the treatment of ischemic HFrEF (CardiALLO), which is actively enrolling, and acute respiratory distress syndrome (ARDS).
Last trade$0.00
Day change$0.00 (0.00%)
Day range$0.765 – $0.811
Volume27,897
Market cap$12M
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$11.96M
Price / earnings
—
Price / book
14.32×
Price / sales
—
EV / sales
—
EV / EBITDA
-1.26×
Profitability
Earnings per share
-$0.51
Return on assets
-249.85%
Return on equity
-918.92%
Dividend yield
0%
Liquidity and leverage
Debt / equity
0×
Current ratio
1.11×
Quick ratio
1.11×
Cash ratio
1.06×
Cash flow
Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$7.62M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for BCDA, quarterly periods
Line item
Q3 FY2026 Sep 30, 2026
Q2 FY2026 Jun 30, 2026
Q1 FY2026 Mar 31, 2026
Q4 FY2025 Dec 31, 2025
Q3 FY2025 Sep 30, 2025
Q2 FY2025 Jun 30, 2025
Q1 FY2025 Mar 31, 2025
Q4 FY2024 Dec 31, 2024
Revenue
$0
$0
$0
$0
$0
$0
$0
$0
Cost of revenue
$0
$0
$0
$0
$0
$0
$0
$0
Gross profit
$0
$0
$0
$0
$0
$0
$0
$0
Selling, general and administrative
$600K
$730K
$1.03M
$885K
$552K
$683K
$1.2M
$906K
Research and development
$1.24M
$893K
$1.24M
$1.13M
$936K
$1.37M
$1.53M
$1.42M
Total operating expenses
$1.84M
$1.62M
$2.27M
$2.01M
$1.49M
$2.05M
$2.73M
$2.32M
Operating income
-$1.84M
-$1.62M
-$2.27M
-$2.01M
-$1.49M
-$2.05M
-$2.73M
-$2.32M
Interest expense
$0
$0
$0
$0
$0
$0
$0
$0
Income before taxes
-$1.82M
-$1.61M
-$2.26M
-$1.98M
-$1.48M
-$2.05M
-$2.71M
-$2.3M
Income taxes
$0
$0
$0
$0
$0
$0
$0
$0
Net income
-$1.82M
-$1.61M
-$2.26M
-$1.98M
-$1.48M
-$2.05M
-$2.71M
-$2.3M
Net income attributable to common shareholders
-$1.82M
-$1.61M
-$2.26M
-$1.98M
-$1.48M
-$2.05M
-$2.71M
-$2.3M
EBITDA
-$1.83M
-$1.62M
-$2.26M
-$2.01M
-$1.48M
-$2.05M
-$2.71M
-$2.31M
Basic earnings per share
-$0.12
-$0.13
-$0.21
-$0.19
-$0.24
-$0.40
-$0.59
-$0.50
Diluted earnings per share
-$0.12
-$0.13
-$0.21
-$0.19
-$0.24
-$0.40
-$0.59
-$0.50
Recent news
Company coverage with links to the original publishers.
BioCardia announced the presentation of its CardiAMP HF II trial design at the HFSA Annual Scientific Meeting. The trial evaluates high-dose autologous cell therapy for patients with ischemic heart failure with reduced ejection fraction. The FDA has granted category B designation for the CardiAMP system and agreed that the ongoing CardiAMP HF II trial may be sufficient to support FDA approval. BioCardia is advancing regulatory submissions with the FDA and Japan's PMDA.
BioCardia completed a capital raise of 3.5 million shares at $1.279 per share, extending cash runway into Q1 2027 and potentially beyond PMDA approval. The company received FDA confirmation that CardiAMP HF II trial may support premarket approval, and obtained Japan PMDA Record of Advice supporting regulatory submission for CardiAMP cell therapy for ischemic heart failure treatment.
BioCardia announced that the FDA identified two regulatory pathways for its Helix Transendocardial Delivery Catheter System, with the FDA's preferred route being simultaneous approval with the CardiAMP cell therapy system. The FDA raised no concerns regarding Helix safety data, device performance, or agent compatibility. An alternative DeNovo pathway was also suggested as a potential route to independent Helix market clearance.
BioCardia, Inc. announced it will hold a conference call on March 24, 2026 at 4:30 PM EDT to provide a corporate update and report financial results for the year ended December 31, 2025. The call will include management remarks followed by a Q&A session and will be available via phone and webcast.
BioCardia announced that the FDA has accepted its pre-submission package for the Helix Transendocardial Delivery Catheter, a minimally invasive device for intramyocardial therapeutic and diagnostic agent delivery. The FDA's Center for Devices and Radiological Health (CDRH) will lead the review in consultation with the Center for Biological Evaluation and Research (CBER). The company expects this approval to support its CardiAMP Cell Therapy program for treating ischemic heart failure.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.